Precision AQ

🎉 We’re thrilled to share that the PM360 Magazine has recognized Precision AQ as a finalist across multiple categories in the 2026 PM360 Trailblazer Awards! 🎉   Our teams have been selected across the following categories:      🏆 Advertising for “My LOPD Turning Point" 🎗️ Direct to Patient Campaign  🎗️Social Media Campaign     🏆 Advertising for “Together in Transplant” with CareDx  🎗️ Corporate Campaign    🏆 Medical Communications for AI Patient Finding Initiative with Pharming Healthcare, Clarity ID, & Trio Health  🎗️ Artificial Intelligence/Data Analytics    Congratulations to our dedicated team members whose expertise helps drive innovation every day, bringing novel therapies faster to patients who need them most. To learn more about Precision AQ’s Advertising and Medical Communications approaches, connect with our team today! https://hubs.ly/Q04s-BzC0

Community practices and academic institutions make drug access decisions differently, and if your field team is using the same playbook for both, you’re leaving access on the table.  At institutions, clinical outcomes dominate regimen selection, while at community practices, economics weigh heaver – especially within pathways, where 100% of community practice respondents cite economic factors in formulary decisions, compared to 64% at institutions.     The 2026 OncoGenius Landscape Report breaks down decision-making by organization type across treatment plans, pathways and formulary, so you can tailor your value story instead of generalizing it.     Learn more: https://hubs.ly/Q04rKg6B0  

🎉 Precision AQ is thrilled to welcome Candice Subero as our new Senior Vice President of Marketing! Candice brings more than 20 years of experience building and scaling marketing organizations across healthcare, life sciences, diagnostics, and healthcare technology. Most recently VP of Global Marketing at OPEN Health, she joins Precision AQ at a pivotal moment — as we continue building a connected commercial platform designed to help biopharmaceutical companies translate science into meaningful patient impact. 🤝 In her role, Candice will lead our Marketing and Lead Generation functions, combining thought leadership, account-based marketing, customer engagement, and AI-powered demand generation to strengthen pipeline and drive scalable growth. "What excites me most about Precision AQ is the opportunity to join an organization that has reimagined what a modern commercial partner can be for healthcare innovators,” said Candice. “Precision has built a uniquely connected model that combines deep therapeutic expertise, end-to-end commercialization capabilities, and powerful data and analytics to support clients from early development through launch and loss of exclusivity.” 💬 Ready to explore how Precision AQ can support your commercialization strategy? Reach out to us today: https://hubs.ly/Q04sMbS40

Medicare Part D's out-of-pocket cap was designed to fix affordability, but the claims data tells a more complicated story. Although annual costs for high-cost specialty patients are meaningfully lower, first-fill abandonment remains high. That’s why the CMS built the Medicare Prescription Payment Plan (M3P) specifically designed to smooth out the first-fill cost — $0 at the counter, repaid in monthly installments. It's mandatory for every plan to offer, free to elect, and available to any enrollee. But only 0.53% of Part D patients have used it. Read Lou DeLoureiro, MBA’s blog to hear him break down this knowledge-and-behavior problem and what manufacturers can do about it: https://hubs.ly/Q04sw0rx0

China’s oncology recruitment runs 2 to 3 times faster than the US. But top investigators are oversubscribed. Cold outreach doesn’t work. And the sites that can deliver aren’t easy to find on your own. The Institute@Precision Asia-Pacific Series is your trusted guide. Our experts. Your advantage. Read the white paper: https://hubs.ly/Q04s9X-X0

In advanced NSCLC, only 21% of patients have biomarker results ready at their first oncology consultation.     When results come back before that visit, median time to treatment start is 16 days. When they’re still pending, it’s 29 days. And for every additional week of delay beyond two weeks, patients with EFR or ALK alterations are nearly twice as likely to start a non-targeted regimen first.      This is the operational gap precision oncology has yet to solve, and it has direct consequences for how and when targeted therapies reach the patients who need them.     Shraddha Kansagra, PharmD, BCOP's latest white paper touches on exactly this.   Read it now: https://hubs.ly/Q04rJ_cB0  

How will #RealWorldEvidence studies affect clinical research and regulatory decision-making in the years to come? From leveraging the patient voice to complementing randomized controlled trials, RWE studies are no longer only supporting post-approval surveillance of drug safety, but are increasingly taking on a greater role in pre-authorization Check out Harpreet Singh, MD's recent article in Nature Medicine for the full article: https://lnkd.in/ehxP5xHX

The 5th Annual Just Move Challenge is bringing our global team together once again. As colleagues across countries work toward our biggest Just Move Challenge yet, they're not only staying active and supporting a great cause, they're also celebrating the communities that shape who they are.   Check out some highlights from our first photo challenge: Community Pride 🌎 Team members were encouraged to share iconic landmarks and local scenes that showcase the communities they call home.

🌍 Does your upcoming research study involve individuals in the European Union? For many research teams, particularly those based in the United States, the EU's General Data Protection Regulation can feel like a distant concern. But #GDPR can play a significant role in how studies are designed, conducted, and documented. 📖 That's why Jacki Chou and Melissa Culhane Maravic put together a report on the 5 things every research team should understand before data collection begins. Make sure you navigate data collection with precision and learn how our #HEOR team can support your #PrimaryDataCollection today: https://lnkd.in/eQY5ThXJ

The healthcare landscape isn't getting simpler. That's why we're building teams that thrive in complexity. Recently recognized as a 2026 MM+M Awards finalist for Market Access Agency of the Year, we continue to redefine what's possible with an access-first approach that brings together insights across payers, providers, patients, and the broader healthcare ecosystem. We're looking for Market Access professionals who are curious, strategic, collaborative, and ready to shape how life-changing therapies reach the people who need them. Ready to make an impact? Explore our open roles: https://hubs.ly/Q04rqJG-0 • Associate Vice President, Clinical Services • Group Account Supervisor • Senior Account Executive • Medical Director • Project Coordinator • Senior Director, Access Experience Team • Senior Scientific Associate / Senior Medical Writer Apply today: https://hubs.ly/Q04rqJG-0